Diagnosis of hepatitis C in pregnant mothers and its transfer pattern in neonates

Hepatitis is the most common liver diseases in the Pakistan caused by blood-borne infection of HCV. Viral transmission is frequent through blood contact. Vertical transmission is transfer of disease from mother to infant. The women who are infected with hepatitis C virus RNA are at high risk of infecting their babies. Actual transmission occurs during labor and at time of delivery when blood of both mother and neonate is in contact with each other. Vertical transmission rate is lowered when mother is HCV RN Anegative. The project was designed to determine the percentage of transmission and prevalence of Hepatitis C virus from mother to neonates. Assessment of the quantitative analysis of RNA levels in mother blood and viraemic status from the early postpartum period onwards of children born to HCV-infected mothers. For the diagnosis of hepatitis C in mothers, blood samples of fifty HCV pregnant women between 23-41 years old were taken. The blood samples were centrifuged at 8,000 rpm and serum was separated and stored at 4°C. The values of the Alanine Aminotransferase was determined at 2nd and 3rd trimester of pregnancy. After extraction HCV-RN Awere transcribed and amplified by PCR. The samples were further authenticated through the Agarose Gel Electrophoresis system and bands were obtained. Nested reverse transcription PCR [RT-PCR] was conducted for the quantitative analysis of HCV-RNA. The results showed that in 66% cases, the mothers had high level of ALT at 2[nd] trimester of pregnancy. Their ALT level was decreased in the 3[rd] trimester of pregnancy. PCR results showed that 40% pregnant women had quantity of HCV-RNA in the range of 1000-10,000 lU/mL and in 18% women were above 100000 The results of spectrophotometer showed that 80% infants had the antibodies against HCV-RNA while only 20% of the neonates did not have antibody right after birth. The 29% babies got HCV-RNA in their serum and became positive for HCV-RNA?

In vitro evaluation of vincristine and fluconazole combination against Candida

Infections associated with cancer are a major scourge and cause of substantial morbidity and mortality in cancer patients. The aim of present study was to appraise the in vitro activity of anticancer agent vincristine and antifungal fluconazole alone and in combination against Candida spp. Results were interpreted in terms of fractional inhibitory concentration index [FICI]. Antifungal activity of fluconazole showed marked synergism when used in combination with vincristine, with FICI ranging from 0.25-0.5 against different Candida spp. Although, the use of vincristine with fluconazole is always disputed due to its side effects including decreased peristalsis, but the present research can help to perform suitability analysis of fluconazole use in life threatening invasive candidiasis associated with cancer patients. In addition, the synergism in antifungal activity after using with vincristine also warrants further research in the direction of minimizing adverse reaction associated with combined use of fluconazole and vincristine